profit from every $100 of sales.
$0$100
InMed Pharmaceuticals
$15.56+17.79% today
-9.0% in 1 year
1-year low $6.151-year high $18.50
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What InMed Pharmaceuticals sold, what it kept, and what it did with the cash.
Sales went from $1.09 million in 2022 to $4.94 million in 2025, with -$8.16 million of profit last year.
SalesProfit
InMed Pharmaceuticals vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| InMed Pharmaceuticals | No profit yet | ||
 Merck KGaA | 24.9× · Fair price | ||
 Takeda Pharmaceutical | 98.3× · Very expensive | ||
 Galderma Group | 87.0× · Very expensive | ||
 Teva Pharmaceutical Industries | 35.1× · Expensive |
AI analysis
An AI analyst reads InMed Pharmaceuticals's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 1 | 4 | 5 | 5 | |
| 1 | 1 | 1 | 2 | |
| -14 | -8 | -8 | -8 | |
| -13 | -8 | -7 | -7 | |
| -19 | -8 | -8 | -8 | |
| -663.40 | -65.00 | -20.20 | -8.36 | |
| 49.9% | 33.9% | 23.9% | 34.5% | |
| -1,266.0% | -202.6% | -176.9% | -160.2% | |
| -1,707.3% | -192.2% | -166.9% | -165.1% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 13 | 14 | 12 | 16 |
| Cash | 6 | 9 | 7 | 11 |
| Total debt | 1 | 0 | 1 | 1 |
| Total liabilities | 4 | 2 | 3 | 2 |
| 9 | 12 | 9 | 13 | |
| 0 | 0 | 0 | 1 | |
| -110.4% | -53.0% | -59.6% | -43.4% | |
| -204.9% | -65.7% | -83.4% | -60.8% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -16 | -7 | -7 | -8 | |
| 0 | 0 | 0 | – | |
| -16 | -7 | -7 | -8 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 1 | 0 | 0 | 0 |
Valuation
- –
- –
- –
- 0.4×
- 1.7×
- –
- –
- -90.9%
- -95.5%
- 0.0%
Profitability
- 34.5%
- -160.2%
- -165.1%
- -27.2%
- -44.5%
- -68.3%
- -10.5%
- -2.0%
- -2.6%
- 0.4%
Growth
- +65.5%
- –
- −11.0%
- –
- +226.5%
Financial health
- -1.4×
- 0.06
- 0.3%
- -21.0×
- 6.99
- 3.11
- 0.07
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 9%of 958
Bottom 1%of 884
Top 8%of 880
Bottom 1%of 988
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 6, 2026 | -0.69 | -94.44 | +99.3% |
| Feb 11, 2026 | -0.51 | – | – |
| Nov 6, 2025 | -0.44 | – | – |
| Sep 23, 2025 | -3.80 | – | – |
| May 12, 2025 | -1.94 | – | – |
| Feb 12, 2025 | -3.64 | – | – |
| Nov 14, 2024 | -54.20 | – | – |
| Sep 27, 2024 | -3.80 | – | – |
News
InMed receives Nasdaq notice over equity requirementSeeking Alpha · Sep 18, 2026The newest story we have is from Sep 18, 2026.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
2/7Passes 2 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
33No pass
Benjamin Graham
73Pass
Philip Fisher
50No pass
Peter Lynch
71Pass
Joel Greenblatt
0No pass
Charlie Munger
42No pass
Terry Smith
42No pass
Questions about InMed Pharmaceuticals
Is InMed Pharmaceuticals a good stock to buy?
A business with weak numbers that is not profitable yet. 2 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the InMed Pharmaceuticals AI analysis
What does InMed Pharmaceuticals do?
InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, develops a pipeline of prescription-based products in the United States. The company operates through two segments, InMed Pharmaceuticals and BayMedica Commercial. It is in Drug Manufacturers - Specialty & Generic.
Does InMed Pharmaceuticals pay a dividend?
No. InMed Pharmaceuticals does not pay a dividend at the moment.
Is InMed Pharmaceuticals stock halal?
No. InMed Pharmaceuticals does not pass our halal screen: its cash and confirmed interest-bearing investments are 130% of its market value, at or above the 33% limit. How we check
How has InMed Pharmaceuticals stock done over the past year?
Down 9.0% over the past twelve months, to $15.56. It traded between $6.15 and $18.50 and is 15.9% below its high.
Who are InMed Pharmaceuticals's competitors?
The largest listed companies in the same industry are Merck KGaA, Takeda Pharmaceutical, Galderma Group and Teva Pharmaceutical Industries. The peers table on this page compares their profit, growth and price with InMed Pharmaceuticals's.
Prices: daily closes to Nov 6, 2026. Fundamentals: company reports via invest-like data.